Skip to main content
Premium Trial:

Request an Annual Quote

FDA Issues Emergency Use Authorization for UCLA NGS-Based SARS-CoV-2 Test

NEW YORK – The US Food and Drug Administration on Tuesday issued Emergency Use Authorization to UCLA's SwabSeq COVID-19 Diagnostic Platform for detecting SARS-CoV-2.

The device is for the qualitative detection of the coronavirus in nasopharyngeal swabs, oropharyngeal swabs, mid-turbinate nasal swabs, and anterior nasal swabs from individuals who are suspected of having COVID-19, the disease caused by SARS-CoV-2.

According to the FDA's authorization letter, the UCLA SwabSeq COVID-19 Diagnostic Platform is a next-generation sequencing-based in vitro diagnostic test and is intended for use by lab personnel trained to use Illumina's MiSeq and NextSeq systems. RNA extraction is performed using Thermo Fisher Scientific's Kingfisher instrument and the company's MagMax Viral/Pathogen Nucleic Acid Isolation kit. Reverse transcription and targeted PCR amplification is performed using Thermo Fisher's TaqPath 1-step RT-qPCR Master Mix with the Veriti 384-well thermal cycler. 

Testing with the platform can be done only at the UCLA Clinical Microbiology Laboratory.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.